Cargando…
Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008233/ https://www.ncbi.nlm.nih.gov/pubmed/36870041 http://dx.doi.org/10.1007/s40291-023-00643-4 |
| _version_ | 1784905712969711616 |
|---|---|
| author | Cammett, Tobin J Garlo, Katherine Millman, Ellen E Rice, Kara Toste, Catherine M Faas, Susan J. |
| author_facet | Cammett, Tobin J Garlo, Katherine Millman, Ellen E Rice, Kara Toste, Catherine M Faas, Susan J. |
| author_sort | Cammett, Tobin J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10008233 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100082332023-03-13 Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab Cammett, Tobin J Garlo, Katherine Millman, Ellen E Rice, Kara Toste, Catherine M Faas, Susan J. Mol Diagn Ther Correction Springer International Publishing 2023-03-04 2023 /pmc/articles/PMC10008233/ /pubmed/36870041 http://dx.doi.org/10.1007/s40291-023-00643-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Cammett, Tobin J Garlo, Katherine Millman, Ellen E Rice, Kara Toste, Catherine M Faas, Susan J. Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab |
| title | Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab |
| title_full | Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab |
| title_fullStr | Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab |
| title_full_unstemmed | Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab |
| title_short | Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab |
| title_sort | correction to: exploratory prognostic biomarkers of complement-mediated thrombotic microangiopathy (cm-tma) in adults with atypical hemolytic uremic syndrome (ahus): analysis of a phase iii study of ravulizumab |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008233/ https://www.ncbi.nlm.nih.gov/pubmed/36870041 http://dx.doi.org/10.1007/s40291-023-00643-4 |
| work_keys_str_mv | AT cammetttobinj correctiontoexploratoryprognosticbiomarkersofcomplementmediatedthromboticmicroangiopathycmtmainadultswithatypicalhemolyticuremicsyndromeahusanalysisofaphaseiiistudyofravulizumab AT garlokatherine correctiontoexploratoryprognosticbiomarkersofcomplementmediatedthromboticmicroangiopathycmtmainadultswithatypicalhemolyticuremicsyndromeahusanalysisofaphaseiiistudyofravulizumab AT millmanellene correctiontoexploratoryprognosticbiomarkersofcomplementmediatedthromboticmicroangiopathycmtmainadultswithatypicalhemolyticuremicsyndromeahusanalysisofaphaseiiistudyofravulizumab AT ricekara correctiontoexploratoryprognosticbiomarkersofcomplementmediatedthromboticmicroangiopathycmtmainadultswithatypicalhemolyticuremicsyndromeahusanalysisofaphaseiiistudyofravulizumab AT tostecatherinem correctiontoexploratoryprognosticbiomarkersofcomplementmediatedthromboticmicroangiopathycmtmainadultswithatypicalhemolyticuremicsyndromeahusanalysisofaphaseiiistudyofravulizumab AT faassusanj correctiontoexploratoryprognosticbiomarkersofcomplementmediatedthromboticmicroangiopathycmtmainadultswithatypicalhemolyticuremicsyndromeahusanalysisofaphaseiiistudyofravulizumab |